Upadacitinib is prescribed for:
- Rheumatoid arthritis
- Psoriatic arthritis
- Atopic dermatitis
- Ulcerative colitis
- Crohn's disease
- Ankylosing spondylitis
- Immunology and dermatologic conditions
Generic Name: Upadacitinib
Brand Names: Rinvoq
Upadacitinib is a selective JAK1 inhibitor for multiple inflammatory conditions including RA, psoriatic arthritis, and atopic dermatitis.
Upadacitinib is prescribed for:
Common side effects:
Serious side effects (boxed warnings apply):
Upadacitinib is a selective JAK1 inhibitor with high efficacy across multiple conditions.
More selective for JAK1 than older JAK inhibitors, though clinical significance of this selectivity is debated.
Approved for more conditions than other JAK inhibitors.
For more information, see MedlinePlus.
This medication is commonly used to treat or manage the following conditions:
Ulcerative colitis is a chronic inflammatory bowel disease causing ulcers and inflammation in the colon and rectum, driven by immune dysfunction, genetics, and environmental factors, leading to symptoms like diarrhea and abdominal pain.
Crohn's disease, an inflammatory bowel disease, causes chronic digestive tract inflammation due to genetic, immune, and environmental factors, leading to debilitating symptoms and complications.
Dermatitis is skin inflammation with varied causes, including irritants, allergens, genetics (eczema), yeast overgrowth, or poor circulation, resulting in itchy rashes and dryness.
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.
Loading questions...
Have questions about Upadacitinib? Get expert answers from Dr. Zimmer.
Privacy: Your questions are posted anonymously for your health privacy. Your name and email are only used for admin purposes.
Questions are reviewed before posting. You'll see your question and Dr. Zimmer's answer below once approved.